Evidence map›Paper›PMID 41783787›Full record

ArticleMolecular therapy. Nucleic acids2026

GalNAc-conjugated siRNA targeting C/EBPβ reverses metabolic dysfunction and restores liver homeostasis in a murine MASLD model.

Shirin Elizabeth Khorsandi, Daniel Vasconcelos, Roman Nicholas, Vikash Reebye, Joanna Nicholls, Mikael Sodergren, James Rowell, Arash Dehkordi, Nagy Habib, Piotr Swiderski and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shirin Elizabeth KhorsandiDepartment of Surgery and Cancer, Imperial College London, London W12 0NN, UK.
Daniel VasconcelosDepartment of Surgery and Cancer, Imperial College London, London W12 0NN, UK.
Roman NicholasDepartment of Surgery and Cancer, Imperial College London, London W12 0NN, UK.
Vikash ReebyeDepartment of Surgery and Cancer, Imperial College London, London W12 0NN, UK.
Joanna NichollsDepartment of Surgery and Cancer, Imperial College London, London W12 0NN, UK.
Mikael SodergrenDepartment of Surgery and Cancer, Imperial College London, London W12 0NN, UK.
James RowellDepartment of Surgery and Cancer, Imperial College London, London W12 0NN, UK.
Arash DehkordiDepartment of Surgery and Cancer, Imperial College London, London W12 0NN, UK.
Nagy HabibDepartment of Surgery and Cancer, Imperial College London, London W12 0NN, UK.
Piotr SwiderskiBeckman Research Institute of City of Hope, Duarte, CA 91010, USA.
John RossiApterna Ltd., London SW1P 2PN, UK.
Kai-Wen HuangDepartment of Surgery & Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CCAAT/enhancer-binding protein beta (C/EBPβ) is a master regulator of hepatic metabolism, inflammation, and fibrosis, making it an attractive but underexploited target for metabolic dysfunction-associated steatotic liver disease (MASLD). Here, we demonstrate that GalNAc-conjugated small interfering RNA (siRNA) targeting C/EBPβ (GalNAc-siCEBPβ) significantly improves liver function and metabolic parameters in a high fat diet (HFD) murine model.

Indexed as

CCAAT/enhancer-binding protein betaC/EBPβhepatic steatosisliver functionMASLDmetabolic-dysfunction-associated steatotic liver diseasemetabolic syndromepre-clinical modelsiRNA therapeutics

Identifiers

PMID41783787
PMCPMC12955106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.